Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

245.80
+5.322.21%
Post-market: 245.800.00000.00%19:30 EDT
Volume:422.91K
Turnover:103.85M
Market Cap:15.96B
PE:16.80
High:246.73
Open:244.60
Low:244.04
Close:240.48
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.77
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.32
PE(LYR):-42.09

Loading ...

Jazz Pharma EVP, Chief Legal Officer Neena Patil disposes of 1,200 shares worth $278,196

Reuters
·
Jun 13

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Edwards Lifesciences (EW)

TIPRANKS
·
Jun 12

Jazz Pharma's Zepzelca Misses Primary Endpoint in Second-Line Lung-Cancer Trial

Dow Jones
·
Jun 12

Jazz Pharmaceuticals Shares Fall 1.7% Premarket After Co's Lung Cancer Drug Fails Late-Stage Trial

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals says Phase 3 LAGOON trial did not meet primary endpoint

TIPRANKS
·
Jun 12

BRIEF-Jazz Pharmaceuticals Provides Update On Zepzelca Phase 3 Trial

Reuters
·
Jun 12

Jazz Pharma's lung cancer drug fails late-stage trial

Reuters
·
Jun 12

Jazz Pharma says Zepzelca Phase 3 LAGOON trial misses overall survival endpoint in second-line SCLC

Reuters
·
Jun 12

Jazz Pharmaceuticals - Lagoon Trial Results Do Not Impact 2026 Guidance

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals - No New Safety Signals Identified for Zepzelca in Lagoon Trial

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals Provides Update on Zepzelca® (Lurbinectedin) Phase 3 Lagoon Trial in Second-Line Small Cell Lung Cancer

THOMSON REUTERS
·
Jun 12

Jazz Pharmaceuticals - Phase 3 Lagoon Trial of Zepzelca in Second-Line Sclc Does Not Meet Primary Endpoint

THOMSON REUTERS
·
Jun 12

BofA Securities Raises Price Target on Jazz Pharmaceuticals to $307 From $281, Maintains Buy Rating

MT Newswires Live
·
Jun 10

Jazz Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Jun 10

Jazz Pharmaceuticals price target raised to $307 from $281 at BofA

TIPRANKS
·
Jun 10

Jazz Pharmaceuticals : Bofa Global Research Raises Price Objective to $307.00 From $281.00

THOMSON REUTERS
·
Jun 10

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 09

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $256 From $230

THOMSON REUTERS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)

TIPRANKS
·
Jun 09

Jazz Pharma director Bruce C. Cozadd disposes of 6,000 shares for USD 1.41 million

Reuters
·
Jun 04